Anavex Life Sciences Corp (AVXL)

[Amatuer17]

Question on R&D
Most of early stage biotechs spend a lot of money on r&d efforts and some trials. They spend a lot of money on r&d efforts to develop tweak compounds.

AVXL has spent a total of $917,000 on r&d last quarter. This seems to include some trial costs as well.

AVXL does not have internal resources/employees to conduct r&d and is not spending much externally - so what kind of actual r&d they are doing?

Seems they got the 2 compounds in the purchase agreement and are just depending on that to move forward. If the current phase results are not as good as some expect - then can they even do anything to improve the compound?

A2-73 seems to cross blood-brain barrier and is non-toxic so is very good candidate for development but does AVXL has any capacity to develop it further?